SinoMab BioScience Limited (HKG:3681)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.580
+0.020 (1.28%)
Apr 17, 2026, 4:08 PM HKT
Market Cap2.16B +61.1%
Revenue (ttm)n/a
Net Income-116.83M
EPS-0.10
Shares Out1.39B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume776,100
Average Volume3,753,500
Open1.560
Previous Close1.560
Day's Range1.560 - 1.610
52-Week Range1.150 - 3.760
Beta0.71
RSI39.82
Earnings DateMar 23, 2026

About SinoMab BioScience

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 61
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3681
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements